WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CSBR stock forecasts and price targets.

Forecast return on equity

Is CSBR forecast to generate an efficient return?

Company
N/A
Industry
67.35%
Market
157.69%

Forecast return on assets

Is CSBR forecast to generate an efficient return on assets?

Company
N/A
Industry
31.29%

CSBR earnings per share forecast

What is CSBR's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.12
Avg 2 year Forecast
$0.10

CSBR revenue forecast

What is CSBR's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$59.7M+3.03%
Avg 2 year Forecast
$66.6M+14.89%
Avg 3 year Forecast
$95.9M+65.55%
CSBR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CSBR revenue growth forecast

How is CSBR forecast to perform vs Biotechnology companies and vs the US market?

Company
18.3%
Industry
38.34%
Market
14.4%
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CSBR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CSBR$6.04N/AN/A
ATYR$0.85$1.00+17.23%Hold
FLNA$1.73N/AN/A
NRXP$2.55$38.00+1,390.20%Strong Buy
LONA$8.86$10.00+12.87%Buy
View Top Biotech Stocks

Champions Oncology Stock Forecast FAQ

What is CSBR's earnings growth forecast for 2026-2027?

(NASDAQ: CSBR) Champions Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.74%.

Champions Oncology's earnings in 2026 is -$2,282,000.On average, 3 Wall Street analysts forecast CSBR's earnings for 2026 to be $1,699,748, with the lowest CSBR earnings forecast at $1,633,091, and the highest CSBR earnings forecast at $1,749,740.

In 2027, CSBR is forecast to generate $1,416,456 in earnings, with the lowest earnings forecast at $1,360,909 and the highest earnings forecast at $1,458,117.

If you're new to stock investing, here's how to buy Champions Oncology stock.

What is CSBR's revenue growth forecast for 2026-2028?

(NASDAQ: CSBR) Champions Oncology's forecast annual revenue growth rate of 18.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.4%.

Champions Oncology's revenue in 2026 is $57,944,000.On average, 3 Wall Street analysts forecast CSBR's revenue for 2026 to be $829,043,512, with the lowest CSBR revenue forecast at $796,520,566, and the highest CSBR revenue forecast at $853,414,892. On average, 3 Wall Street analysts forecast CSBR's revenue for 2027 to be $924,432,120, with the lowest CSBR revenue forecast at $888,187,504, and the highest CSBR revenue forecast at $951,622,525.

In 2028, CSBR is forecast to generate $1,332,093,784 in revenue, with the lowest revenue forecast at $1,279,851,545 and the highest revenue forecast at $1,371,268,520.

What is CSBR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CSBR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.29%.

What is CSBR's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CSBR) Champions Oncology's current Earnings Per Share (EPS) is -$0.17. On average, analysts forecast that CSBR's EPS will be $0.12 for 2026, with the lowest EPS forecast at $0.12, and the highest EPS forecast at $0.13. In 2027, CSBR's EPS is forecast to hit $0.10 (min: $0.10, max: $0.11).

What is CSBR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CSBR) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.